Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary... ( Nordic Biotech II K/S and MPM BioVe...)

HOME >> MEDICINE >> TECHNOLOGY

Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema

Date:2/28/2008

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million

investment on top of $75 million previous investment

AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.

"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."

"We are investing in the clear value we see in Arriva's late-stage inhaled protein rAAT, a replacement product for the treatment of hereditary emphysema," said Florian Schonharting, partner of Nordic Biotech. "Our goal with Arriva is to provide financing and through board participation, help the company become a recognized, fully integrated biotech concern," added Christian Hansen, partner of Nordic Biotech.

"MPM has been a supporter of Arriva and the company's mission since 2002," said Ansbert Gadicke, General Partner, MPM Capital. "We continue to believe that there is significant potential in the company's respiratory product pipeline and are involved in this financing because we anticipate that Arriva will successfully capitalize on its IP and other assets."

About Arriva:

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonar
'/>"/>

SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

(Date:5/22/2013)... Advanced Prenatal Therapeutics (APT), a privately held ... alleviate the high blood pressure and other symptoms associated ... be the first medical device specifically designed to treat ... Every year, preeclampsia affects approximately 300,000 pregnant ... It is characterized by high blood pressure and proteinuria ...

(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... is investigating potential claims on behalf of purchasers ... or the "Company") (NasdaqGS: AMAG -News). The investigation ... violated federal securities laws. On May ... 10.73% during intraday trading after the company announced ...

(Date:5/22/2013)... 2013 The Leukemia & Lymphoma Society (LLS) is ... LLC, a joint venture between ImmunGene and Caliber, to ... Phase I clinical trial for a novel fusion protein ... patients with indolent lymphomas who do not respond to ... IGN002, is a new class of biotherapeutics produced by ...

Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4

[0] Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia [0] Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.[0] The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients

... 2012 Niagara Thermal Products LLC is pleased to announce ... acquisition brings together two highly regarded names in the ... in the aerospace, defense and electronics markets. ... addition of Kittredge,s industry recognized dip brazing, welding, machining ...

... N.C., Jan. 23, 2012 As the influence of Managed ... that biopharma companies carry out as part of interacting ... device leaders have placed an increased importance on these ... closely intertwined with marketplace success. On average, ...

Cached Medicine Technology:Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 2 Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 3 Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 2 Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 3

Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc.Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations

(Date:5/22/2013)... 2013 The surging growth in specialty ... through marketing claims to compare mattresses often proves a ... a bed blog , offers shoppers faced with this ... their latest article. , Titled “ Mattress Comparison Overview ... guides readers through the basics of innerspring beds as ...

(Date:5/22/2013)... TX (PRWEB) May 22, 2013 ... sustainable practices in the textile industry, today released ... findings demonstrate that organic cotton production dropped 8% ... dramatic than the staggering 37% drop in 2010-11. ... production. , The report, Textile Exchange’s seventh, ...

(Date:5/22/2013)... Dr. Andrew Satlin offers patients with gum disease ... Assisted New Attachment Procedure (LANAP). May is Stroke Awareness Month, ... gum disease and stroke. Periodontal disease is one of the ... is linked to an increased risk for strokes because of ... pockets. , Periodontal disease is essentially an infection of ...

(Date:5/22/2013)... TWITTER: @the_USO & @SesameStreet are proud to ... in the next 6 months! , Today, the ... came together to show their heartfelt thanks to those who currently ... for distribution to our servicemen and women. The group was ... and the USO as well as the success of the ...

(Date:5/22/2013)... CHARLOTTE, (PRWEB) May 22, 2013 The ... fight against muscular dystrophy at the annual Charlotte Muscle ... $300,000 to help Charlotte-area families living with muscle disease. ... this year's event to support MDA families,” said MDA ... heroes who were partnered with a "Buddy" to make ...

Breaking Medicine News(10 mins):Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 2 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 3 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 4 Health News:For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment 2 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 2 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 3 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 4 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 5 Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2

[0] Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands [0] Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report [0] For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment [0] The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC [0] Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease

... two surveys find , , THURSDAY, May 15 (HealthDay News) -- ... devices aren,t aware of recent recalls and don,t understand the ... they point to a lack of understanding among both doctors ... treat it, said Dr. Bruce Wilkoff, director of cardiac and ...

... minSURG Corporation, a,subsidiary of Orthopedic Development Corporation, ... used to treat chronic facet-oriented back,pain or to ... fuse each of the two facet joints in ... solutions to treat intractable back pain without,precluding other ...

... May 15 Nephros, Inc. (Amex: NEP ),announced today ... Recent Highlights -- Increased product revenues by ... U.S. trial for the OLpur(TM) H2H(TM) ... Joleen C. Turner as VP of Marketing and Business Development ...

... ... as a ,highlighted, poster at American Heart,Association Conference on Arteriosclerosis, Thrombosis and Vascular ... ... Inc. (TSX: PMD; Amex: PME) today announced unaudited financial,results for the first quarter ...

... hospital, they,re twice as likely to be injured, so prevention ... -- Stroke patients have a high risk of falling after ... , The University of Auckland researchers added that prevention programs ... a stroke fall almost twice as often as people who ...

... is,prepared to provide $10 million to support relief efforts ... This,contribution will assist the Red Cross Society of China, ... earthquake struck on,Monday, May 12. According to the latest ... many more are missing or trapped by debris., ...

Heart Device Recipients Often Not Aware of Recalls TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels Nephros Reports 2008 First Quarter Financial Results PreMD Reports First Quarter Results Stroke Patients at High Risk for Falls The American Red Cross Commits $10 Million to Assist China Earthquake Survivors

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Trig Tricyclic Antidepressant, Total Tricyclic Antidepressant Identification Quantitative, Serum Trichloraethanol (Chloral Hydrate Metabolite)